Vir Biotechnology Inc. reported its third quarter 2025 financial results and provided a corporate update. The company announced completion of enrollment for ECLIPSE 1 approximately two months ahead of schedule, with ECLIPSE 2 and ECLIPSE 3 studies continuing to enroll strongly. Topline data for all three studies are expected in the first quarter of 2027. Vir also plans a comprehensive data update for VIR-5500, a PSMA-targeting PRO-XTEN® dual-masked T-cell engager, in the first quarter of 2026 and has dosed the first patient in a Phase 1 study of VIR-5500 combined with androgen receptor pathway inhibitors in first-line metastatic castration-resistant prostate cancer. Financially, the company reported cash and investments of $810.7 million as of September 30, 2025, and expects its financial runway to extend into mid-2027. Selling, general and administrative expenses for the quarter were $22.2 million, down from $25.7 million in the same period in 2024, largely due to cost-saving measures. The $75.0 million milestone payment related to the VIR-5525 program was paid from escrow and did not impact the company's reported cash position or runway.